291 related articles for article (PubMed ID: 14763163)
1. Targeting PI3K-AKT pathway for cancer therapy.
Lu Y; Wang H; Mills GB
Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
[TBL] [Abstract][Full Text] [Related]
2. PI3K/Akt signalling pathway and cancer.
Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
[TBL] [Abstract][Full Text] [Related]
3. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
7. PI3K-Akt pathway: its functions and alterations in human cancer.
Osaki M; Oshimura M; Ito H
Apoptosis; 2004 Nov; 9(6):667-76. PubMed ID: 15505410
[TBL] [Abstract][Full Text] [Related]
8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
11. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Mills GB; Kohn E; Lu Y; Eder A; Fang X; Wang H; Bast RC; Gray J; Jaffe R; Hortobagyi G
Semin Oncol; 2003 Oct; 30(5 Suppl 16):93-104. PubMed ID: 14613030
[TBL] [Abstract][Full Text] [Related]
12. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
14. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
Gao N; Nester RA; Sarkar MA
Toxicol Appl Pharmacol; 2004 Apr; 196(1):124-35. PubMed ID: 15050414
[TBL] [Abstract][Full Text] [Related]
15. Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells.
Zingg D; Riesterer O; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Cancer Res; 2004 Aug; 64(15):5398-406. PubMed ID: 15289348
[TBL] [Abstract][Full Text] [Related]
16. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
18. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.
Chang F; Lee JT; Navolanic PM; Steelman LS; Shelton JG; Blalock WL; Franklin RA; McCubrey JA
Leukemia; 2003 Mar; 17(3):590-603. PubMed ID: 12646949
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K-Akt pathway in kidney cancer.
Park JY; Lin PY; Weiss RH
Expert Rev Anticancer Ther; 2007 Jun; 7(6):863-70. PubMed ID: 17555396
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.
Chen YL; Law PY; Loh HH
Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):575-89. PubMed ID: 16305480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
